Nav: Home

Evaluating the benefits of health insurance on cancer care

January 27, 2017

Jan, 27, 2017, Lebanon, N.H. -- Millions of Americans acquire their health insurance under the Affordable Care Act, including individuals from disadvantaged communities (as defined by a summary measure comprised of U.S. Census measures of income, education, and employment). Patients with one of the four leading causes of cancer deaths have lower rates of cancer-specific survival based on where they live, specifically based on their social determinants of health. The extent to which health insurance can ease the effects of these social determinants of health on cancer care is the subject of current research led by Dartmouth-Hitchcock Norris Cotton Cancer Center's Sandra Wong, MD, Professor and Chair of Surgery, Senior Vice President of the Surgical Services Line and Interim Vice President of the Oncology Service Line. Her work, "The impact of health insurance status on cancer care in disadvantaged communities" was recently published in the journal, Cancer.

Wong's study finds that the effect of having health insurance appears to be more pronounced in those from disadvantaged communities, compared to more advantaged communities, through better access to cancer care. However, the differences attributed to social determinants of health were not fully mitigated. Insured patients from less disadvantaged communities still had higher odds of receiving cancer-directed surgery and better cancer-specific survival than insured patients from disadvantaged communities. Interestingly, Medicaid insurance was associated with a much more modest survival benefit in those from disadvantaged communities.

"We were seeking to examine the differential impact of health insurance on cancer care across communities with varying social determinants of health" says Wong. "To the best of our knowledge, this is the first national study to explore the interplay between health insurance and social determinants of health and the resultant impact on cancer care and cancer outcomes."

The Dartmouth-Hitchcock study collected Surveillance, Epidemiology, and End Results registry data for 364,507 patients diagnosed with the four highest causes of cancer deaths: breast cancer, prostate cancer, lung cancer, and colorectal cancer, between 2007 and 2011. In the entire cohort, 304,224 patients (83.5%) were insured, 43,572 (12%) had Medicaid coverage, and 16,711 (4.6%) were uninsured. A social determinant score was determined based on five measures of wealth, education, and employment. In order to quantify the differences in the effects of health insurance on these varying social strata, patients were stratified into quintiles, the lowest quintile representing the most disadvantaged communities. Logistic regression and Cox proportional hazards models were used to estimate associations and cancer-specific survival within each quintile. The models were respectively adjusted for age, sex, race/ethnicity, marital status, cancer type, and stage.

Researchers found a consistent relation between a community's relative advantage and cancer-specific care, survival and outcomes. Although health insurance appeared to lessen this relation, it did not fully eliminate the differences caused by the measured social determinants of health. Notably, patients from disadvantaged communities had a larger relative benefit from health insurance, which demonstrated their need for improved access to care.

"These data will help inform ongoing healthcare payment reform efforts," says Wong. "Those from the most disadvantaged communities benefit the most from health insurance, but there are still disparities compared the most advantaged communities. Provisions for insurance are necessary but insufficient to eliminate inequities in cancer outcomes. Attention is also needed for community-level efforts and closer examination of the social determinants of health."
This work was supported by the Agency for Healthcare Research and Quality (T32 HS000053-22), the National Institutes of Health/National Cancer Institute (1K07 CA163665-22), the American Society of Colon and Rectal Surgeons Research Foundation, the Agency for Healthcare Research and Quality (1K08 HS20937-01), and the American Cancer Society (RSG-12-269-01-CPHPS).

About Norris Cotton Cancer Center at Dartmouth-Hitchcock

Norris Cotton Cancer Center combines advanced cancer research at Dartmouth's Geisel School of Medicine with patient-centered cancer care provided at Dartmouth-Hitchcock Medical Center in Lebanon, NH, at Dartmouth-Hitchcock regional locations in Manchester, Nashua and Keene, NH, and St. Johnsbury, VT, and at partner hospitals throughout New Hampshire and Vermont. It is one of 45 centers nationwide to earn the National Cancer Institute's "Comprehensive Cancer Center" designation. Learn more about Norris Cotton Cancer Center research, programs, and clinical trials online at

Dartmouth-Hitchcock Medical Center

Related Prostate Cancer Articles:

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.
Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.
CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.
Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.
Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.
More Prostate Cancer News and Prostate Cancer Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Erasing The Stigma
Many of us either cope with mental illness or know someone who does. But we still have a hard time talking about it. This hour, TED speakers explore ways to push past — and even erase — the stigma. Guests include musician and comedian Jordan Raskopoulos, neuroscientist and psychiatrist Thomas Insel, psychiatrist Dixon Chibanda, anxiety and depression researcher Olivia Remes, and entrepreneur Sangu Delle.
Now Playing: Science for the People

#537 Science Journalism, Hold the Hype
Everyone's seen a piece of science getting over-exaggerated in the media. Most people would be quick to blame journalists and big media for getting in wrong. In many cases, you'd be right. But there's other sources of hype in science journalism. and one of them can be found in the humble, and little-known press release. We're talking with Chris Chambers about doing science about science journalism, and where the hype creeps in. Related links: The association between exaggeration in health related science news and academic press releases: retrospective observational study Claims of causality in health news: a randomised trial This...